SavedAdd your journal

Journals / Eurasian Journal of Medicine and Oncology / 2019 / Cilt: 3 - Sayı: 2

Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer

Hang NGUYEN
Thinh HOANG
Diep NGUYEN
Thong PHAM
Thang PHAN
Pages
101–107
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Histologic grade, TTF1 marker, and sample type are independent factors for the incidence of EGFR mutations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to describe the characteristics of epidermal growth factor receptor (EGFR) mutations in correlation with clinical features of Vietnamese non-small cell lung cancer (NSCLC), and identify the predictive factor for the incidence of EGFR mutations.
📊
Key Findings & Data:Methods: A total of 1.548 newly diagnosed NSCLC patients were selected for this retrospective study.
💡
Conclusion & Impact:Histologic grade, TTF1 marker, and sample type are independent factors for the incidence of EGFR mutations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to describe the characteristics of epidermal growth factor receptor (EGFR) mutations in correlation with clinical features of Vietnamese non-small cell lung cancer (NSCLC), and identify the predictive factor for the incidence of EGFR mutations. Methods: A total of 1.548 newly diagnosed NSCLC patients were selected for this retrospective study. EGFR mutations were detected in the tumor, lymph node tissue and pleural fluid by the pyrosequencing method. Results: EGFR mutations were detected in 623 patients (40.2%). Mutations were more frequent in the female patient (p<0.001), in adenocarcinoma (p=0.004), in pleural effusion sample (p=0.002), in the low-intermediate grade of the tumor (p<0.001), and in those with CK7-positive (p=0.001) and TTF1-positive result (p<0.001). Notably, the low grade of the tumor (p<0.001), TTF1-positive marker (p=0.001) and pleural fluid (p=0.002) were detected as independent factors for the higher incidence of EGFR mutations in multivariable analysis. In addition, CK7 marker played the role as an independent factor when TTF1 marker was not applied (p=0.011). Conclusion: EGFR mutations occur with high frequency in Vietnamese NSCLC patients. Histologic grade, TTF1 marker, and sample type are independent factors for the incidence of EGFR mutations.

🔖

Cite This Article

NGUYEN, H., HOANG, T., NGUYEN, D., PHAM, T., PHAN, T. (2019). Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. Eurasian Journal of Medicine and Oncology, Cilt: 3 - Sayı: 2, 101–107. https://ajindex.com/articles/125551

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al; Global Burden of Disease Cancer Collaboration. Global, Regional, and National cancer incidence, Mortality, Years of life lost, Years lived with disability, and Disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524–48. 2. Cheng L, Alexander RE, MacLennan GT, Cummings OW, Montironi R, Lopez-Beltran A, et al. Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology 2012;25:347–69. 3. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small cell lung cancer with Erlotinib or Gefitinib. N Engl J Med 2011;364:947–55. 4. Kohler J, Schuler M. Afatinib, Erlotinib and Gefitinib in the firstline therapy of EGFR mutation-positive lung adenocarcinoma: A review. Onkologie 2013;36:510–8. 5. Rossel R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al; Spanish Lung Cancer Group. Screening for Epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958–67. 6. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892–1. 7. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014;9:154–62. 8. Arrieta O, Cardona A, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramuglia G, et al. Updated frequency of EGFR and KRAS mutations in Non-small-cell lung cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol 2015;10:838–43. 9. Vu HA, Xinh PT, Ha HT, Hanh NT, Bach ND, Thao DT, et al. Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer. Asia Pac J Clin Oncol 2016;12:86– 90. 10. Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006;94:896–903. 11. Wei W, Mao NQ, Ning SF, Li JL, Liu HZ, Xie T, et al. An analysis of EGFR mutations among 1506 cases of Non-small cell lung cancer patients in Guangxi, China. Plos One 2016;11:e0168795. 12. Zhang